FOSTER CITY, Calif., September 20, 2021 (GLOBE NEWSWIRE) – Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat certain of the world’s most common and deadly infectious diseases, announced today that it has appointed Annie Drapeau and Teri Loxam to its Board of Directors. As part of these appointments, longtime board members Patrick Heron and Rob Hopfner have resigned from the board.
âWe are delighted to welcome Annie and Teri, two accomplished leaders with extensive experience in the biopharmaceutical and technology industries, to our board of directors,â said Grant Pickering, CEO and co-founder of Vaxcyte. âAs Vaxcyte continues to advance our core program, VAX-24, a 24-valent pneumococcal conjugate vaccine candidate, toward clinical proof of concept, we will benefit from the additional skills and expertise that Annie and Teri bring to our board of directors. “
Mr. Pickering added, âI would also like to thank Patrick and Rob of Frazier Healthcare Partners and Pivotal bioVenture Partners, respectively, for their support and service on our Board of Directors. Both have made significant contributions that go far beyond co-leading one of our early grants that helped put Vaxcyte on track to achieve what it is today.
âThis is an exciting time for Vaxcyte as the organization continues to develop and advance its vaccine pipeline,â said Drapeau. âHaving spent my career advancing high growth organizations, such as Moderna and Toast, I am delighted to join the Vaxcyte Board of Directors and contribute my experience to this transformative vaccine company. “
Ms Loxam added: âAt a time when vaccines have never been more important, I am delighted to join the board of directors of Vaxcyte to help the company achieve its mission of providing the next generation of vaccines against some of the most common and deadly infectious diseases in the world. . “
About Ms. Drapeau
Ms. Drapeau is Chief People Officer at Toast, the end-to-end platform designed for restaurants. With over 25 years of experience in human resources, strategy and finance, she was previously the Director of Human Resources at Moderna, helping to evolve the company as it expanded to multiple programs. clinical stage across a range of modalities. Ms. Drapeau was also an operating partner at Bain Capital, helping to implement talent management strategies across the private equity portfolio. She also served as Chief People Officer at Iron Mountain, VistaPrint and Digitas, and began her career in finance roles at JP Morgan and PepsiCo. Ms. Drapeau holds a BA from Bucknell University, where she serves on the Board of Trustees, and an MBA from Tuck School at Dartmouth College.
About Ms. Loxam
Ms. Loxam is currently Chief Financial Officer of SQZ Biotechnologies, overseeing the company’s financial operations, including financial strategy, accounting, financial planning and analysis, risk management, tax and treasury as well as investor relations and communications / public relations. Since joining SQZ Biotechnologies in August 2019, she has helped raise more than $ 200 million for the company, including the company’s initial public offering in November 2020. Prior to joining SQZ Biotechnologies, Ms. Loxam was Senior Vice President of Investor Relations and Global Communications at Merck. . In this role, she led internal and external global communications efforts, which included Merck’s portfolio of therapeutics and vaccines. Previously, she was Vice President of Investor Relations for IMAX Corporation, where she helped lead the company’s IPO on the Hong Kong Stock Exchange. Ms. Loxam has also spent over a decade at Bristol-Myers Squibb in a variety of increasingly responsible roles in strategy, treasury and investor relations. She holds a BA in Biology from the University of Victoria, BC Canada and an MBA from the University of California, Irvine.
Vaxcyte is a next-generation vaccine company that seeks to improve global health by developing superior and innovative vaccines designed to prevent or treat some of the world’s most common and deadly infectious diseases. The Company’s cell-free protein synthesis platform, comprising the XpressCF â¢ platform, exclusively licensed from Sutro Biopharma, Inc., as well as the proprietary know-how of Vaxcyte, enables the design and production of vectors proteins and antigens, the essential building blocks of vaccines, in ways the Company believes conventional vaccine technologies currently cannot do. Vaxcyte’s lead vaccine candidate, VAX-24, is a 24-valent preclinical broad-spectrum pneumococcal (PCV) conjugate vaccine under development for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with extensive coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent group A streptococcal infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or arrest the progression of periodontal disease by targeting the key pathogen responsible for this chronic oral inflammatory disease. For more information visit www.vaxcyte.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements relating to the benefits of Vaxcyte’s vaccine candidates; the process and timing of the anticipated future development of Vaxcyte vaccine candidates; and other statements which are not historical facts. The words “believe”, “might”, “expect”, “could”, “possible”, “should”, “should” and similar expressions are intended to identify forward-looking statements, although all forward-looking statements do not contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in these forward-looking statements due to risks and uncertainties, including, without limitation, risks. related to Vaxcyte’s product development programs. , including development timelines, success and timing of the chemistry, manufacturing and controls and associated manufacturing activities, potential delays or failure to obtain and maintain the required regulatory approvals for its vaccine candidates , and the risks and uncertainties inherent in the preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and the sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described in more detail in documents filed by Vaxcyte with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 or in d ‘other documents that Vaxcyte files or subsequently provides in the second. Vaxcyte assumes no obligation or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations. Readers should not rely on any information in this press release as being up to date or accurate after the date of publication.
Janet Graesser, Vice-President, Corporate Communications and Investor Relations